CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer

Monique C. de Jong, Jimmy Pramana, Jacqueline E. van der Wal, Martin Lacko, Carine J. Peutz-Kootstra, Jos M. de Jong, Robert P. Takes, Johannes H. A. M. Kaanders, Bernard F. van der Laan, Jasper Wachters, Jeroen C. Jansen, Coen R. Rasch, Marie-Louise F. van Velthuysen, Reidar Grenman, Frank J. Hoebers, Ed Schuuring, Michiel W. M. van den Brekel, Adrian C. Begg

Research output: Contribution to journalArticleAcademicpeer-review


Purpose: To find molecular markers from expression profiling data to predict recurrence of laryngeal cancer after radiotherapy. Experimental Design: We generated gene expression data on pre-treatment biopsies from 52 larynx cancer patients. Patients developing a local recurrence were matched for T-stage, subsite, treatment, gender and age with non-recurrence patients. Candidate genes were then tested by immunohistochemistry on tumor material from a second series of 76 patients. Both series comprised early stage cancer treated with radiotherapy alone. Finally, gene expression data of eight larynx cancer cell lines with known radiosensitivity were analyzed. Results: Nineteen patients with a local recurrence were matched with 33 controls. Gene sets for hypoxia, proliferation and intrinsic radiosensitivity did not correlate with recurrence, whereas expression of the putative stem cell marker CD44 did. In a supervised analysis, probes for all three splice variants of CD44 on the array appeared in the top 10 most significantly correlated with local recurrence. Immunohistochemical analysis of CD44 expression on the independent validation series confirmed CD44's predictive potential. In 8 larynx cancer cell lines, CD44 gene expression did not correlate with intrinsic radiosensitivity although it did correlate significantly with plating efficiency, consistent with a relationship with stem cell content. Conclusions: CD44 was the only biological factor tested which significantly correlated with response to radiotherapy in early stage larynx cancer patients, both at the mRNA and protein levels. Further studies are needed to confirm this and to assess how general these findings are for other head and neck tumor stages and sites. Clin Cancer Res; 16(21); 5329-38.
Original languageEnglish
Pages (from-to)5329-5338
JournalClinical Cancer Research
Issue number21
Publication statusPublished - 1 Nov 2010

Cite this